Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting.
Jean-Baptiste AssiéChristos ChouaidHilario NunesDorothée ReynaudAnne-Françoise GaudinValentine GrumbergRonan JolivelBaptiste JouanetonFrançois-Emery CottéBoris DuchemannPublished in: Therapeutic advances in medical oncology (2023)
In this large cohort of aNSCLC patients with ILD, outcomes are similar to those obtained in the non-ILD population. Immunotherapy could be beneficial for these patients.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- advanced non small cell lung cancer
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- end stage renal disease
- epidermal growth factor receptor
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- type diabetes
- metabolic syndrome
- patient reported outcomes
- weight loss
- skeletal muscle
- combination therapy